Imagenebio, INC. (IMA) — SEC Filings

Q: What are the key financial highlights for Imagenebio, INC.?

Key financial highlights for Imagenebio, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Imagenebio, INC.?

Key executives at Imagenebio, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Imagenebio, INC. stock?

Risk factors for Imagenebio, INC. (IMA) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Imagenebio, INC.?

Forward-looking statements and predictions from Imagenebio, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Imagenebio, INC.. Recent 4 filing on Apr 16, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Imagenebio, INC. on SEC EDGAR

Overview

Imagenebio, INC. (IMA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 16, 2026: On April 16, 2026, David P. Bonita reported a change in beneficial ownership of securities for ImageneBio, Inc. The filing, dated April 14, 2026, details transactions related to his holdings.

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 42 neutral, 3 mixed. The dominant filing sentiment for Imagenebio, INC. is neutral.

Filing Type Overview

Imagenebio, INC. (IMA) has filed 1 4, 1 424B3, 23 8-K, 1 EFFECT, 6 10-Q, 1 S-1, 1 8-K/A, 2 10-K, 1 SC 13G, 6 SC 13G/A, 1 DEFA14A, 1 DEF 14A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (45)

ImageneBio Insider Trading Update — 4 · Apr 16, 2026 Risk: low
On April 16, 2026, David P. Bonita reported a change in beneficial ownership of securities for ImageneBio, Inc. The filing, dated April 14, 2026, details transa
ImageneBio Files 424B3 Prospectus — 424B3 · Apr 13, 2026 Risk: low
ImageneBio, Inc. filed a 424B3 prospectus on April 13, 2026, detailing its offering. The company, located at 12526 High Bluff Drive, San Diego, CA 92130, is inv
8-K Filing — 8-K · Apr 13, 2026
ImageneBio, Inc. Registration Statement Declared Effective — EFFECT · Apr 6, 2026 Risk: medium
ImageneBio, Inc. filed an EFFECT form, indicating the effectiveness of a registration statement, on April 6, 2026. The filing relates to Act 33 and has File No.
ImageneBio, Inc. Reports Board and Executive Compensation Changes — 8-K · Dec 18, 2025 Risk: medium
ImageneBio, Inc. announced on December 12, 2025, a change in its board of directors and executive compensation arrangements. Specifically, the company reported
ImageneBio, Inc. Files 8-K — 8-K · Nov 19, 2025 Risk: low
ImageneBio, Inc. filed an 8-K on November 19, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known a
ImageneBio's Losses Mount Amid Soaring R&D, Cash Position Strengthens Post-PIPE — 10-Q · Nov 12, 2025 Risk: high
ImageneBio, Inc. reported a significant increase in net loss for the three months ended September 30, 2025, reaching $24.779 million, up from $3.183 million in
8-K Filing — 8-K · Nov 5, 2025
ImageneBio Reports Material Agreement Entry & Termination — 8-K · Oct 29, 2025 Risk: medium
ImageneBio, Inc. (formerly Ikena Oncology, Inc.) filed an 8-K on October 29, 2025, reporting on events that occurred on October 23, 2025. The filing indicates b
ImageneBio Reports Director/Officer Changes & Compensation Updates — 8-K · Oct 22, 2025 Risk: medium
ImageneBio, Inc. filed an 8-K on October 22, 2025, reporting changes effective October 21, 2025. The filing indicates a departure of directors or certain office
ImageneBio, Inc. Reports Leadership Changes and Compensation Updates — 8-K · Oct 10, 2025 Risk: medium
On October 10, 2025, ImageneBio, Inc. filed an 8-K report detailing changes in its leadership and executive compensation. The filing indicates the departure of
ImageneBio Debuts on Nasdaq, Eyes $257B Immunology Market with Lead Asset IMG-007 — S-1 · Sep 8, 2025 Risk: high
ImageneBio, Inc. (IMA) is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune, immunological, and inflammatory (I&I) indic
ImageneBio Files 8-K/A Amendment on Asset Acquisition — 8-K/A · Aug 12, 2025 Risk: low
ImageneBio, Inc. filed an amendment (8-K/A) on August 12, 2025, to a previous filing concerning the completion of an acquisition or disposition of assets. The a
ImageneBio Changes Certifying Accountant to 03 Life Sciences — 8-K · Aug 5, 2025 Risk: low
ImageneBio, Inc. (formerly Ikena Oncology, Inc.) announced on August 2, 2025, a change in its certifying accountant to 03 Life Sciences. This change was effecti
ImageneBio Appoints Dr. David R. Walt to Board — 8-K · Aug 1, 2025 Risk: low
ImageneBio, Inc. announced on July 28, 2025, a change in its board of directors. Dr. David R. Walt has been appointed as a Class II director, effective immediat
ImageneBio Reports Multiple Material Events — 8-K · Jul 29, 2025 Risk: medium
ImageneBio, Inc. (formerly Ikena Oncology, Inc.) filed an 8-K on July 29, 2025, reporting several material events. These include entering into a material defini
Imigenebio, Inc. Changes Name from Ikena Oncology, Inc. — 8-K · Jul 25, 2025 Risk: low
On July 25, 2025, Imigenebio, Inc. (formerly Ikena Oncology, Inc.) filed an 8-K report. The company, incorporated in Delaware, is located at 12526 High Bluff Dr
Ikena Oncology Files 8-K Report — 8-K · Jul 24, 2025 Risk: low
On July 24, 2025, Ikena Oncology, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transac
Ikena Narrows Losses Amid Inmagene Merger Ahead of Immunology Pivot — 10-Q · Jul 24, 2025 Risk: high
Ikena Oncology, Inc. reported a net loss of $13.5 million for the three months ended June 30, 2025, a significant improvement from the $23.2 million net loss in
Ikena Oncology Files 8-K: Other Events Reported — 8-K · Jul 22, 2025 Risk: medium
On July 22, 2025, Ikena Oncology, Inc. filed an 8-K report. The filing indicates an "Other Events" item, suggesting a significant development not covered by oth
Ikena Oncology Reports Director Changes and Executive Compensation Adjustments — 8-K · Jul 16, 2025 Risk: medium
On July 15, 2025, Ikena Oncology, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a depart
Ikena Oncology Files 8-K on Officer/Director Changes — 8-K · Jul 15, 2025 Risk: medium
On July 15, 2025, Ikena Oncology, Inc. filed an 8-K report detailing several key events. These include the departure of directors or certain officers, the elect
Ikena Oncology Files 8-K Report — 8-K · Jul 11, 2025 Risk: low
On July 11, 2025, Ikena Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating upd
Ikena Oncology Files 8-K Report — 8-K · Jul 1, 2025 Risk: low
On July 1, 2025, Ikena Oncology, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Ex
Ikena Oncology Files Q1 2025 10-Q, Details Merger & Loan — 10-Q · May 8, 2025 Risk: medium
Ikena Oncology, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations, including detai
Ikena Oncology Files 2024 10-K, Cites Pionyr Acquisition — 10-K · Mar 6, 2025 Risk: medium
Ikena Oncology, Inc. filed its 2024 10-K on March 6, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in Delaware, is in t
Ikena Oncology Files 8-K: Material Agreements, Control Changes — 8-K · Dec 23, 2024 Risk: medium
On December 23, 2024, Ikena Oncology, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agreement
SC 13G Filing — SC 13G · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 13, 2024
Ikena Oncology Q3 2024 Update — 10-Q · Nov 7, 2024 Risk: medium
Ikena Oncology, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the third quarter of 20
Ikena Oncology Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
Ikena Oncology, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and results of operations, including de
Ikena Oncology Appoints New Chief Medical Officer — 8-K · Jul 12, 2024 Risk: medium
Ikena Oncology, Inc. announced on July 8, 2024, the appointment of Dr. Jeffrey W. Almasleh as Chief Medical Officer. Dr. Almasleh brings extensive experience in
Ikena Oncology Reports on Shareholder Vote — 8-K · Jun 10, 2024 Risk: low
Ikena Oncology, Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of security holders on June 7, 2024. The filing details the company
Ikena Oncology Terminates Bristol Myers Squibb Deal for IK-750 — 8-K · May 28, 2024 Risk: medium
On May 23, 2024, Ikena Oncology, Inc. announced the termination of its collaboration and license agreement with Bristol Myers Squibb for the development of IK-7
Ikena Oncology, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: medium
Ikena Oncology, Inc. (IMA) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Ikena Oncology reported financial results for the quarter ended March 3
Ikena Oncology 2024 Annual Meeting Proxy Statement — DEFA14A · Apr 26, 2024 Risk: low
Ikena Oncology, Inc. is holding its 2024 Annual Meeting on June 6, 2024, where shareholders will vote on important matters. The company is based in Boston, MA,
Ikena Oncology Announces 2024 Annual Meeting of Stockholders on June 7 — DEF 14A · Apr 26, 2024 Risk: low
Ikena Oncology, Inc. (IMA) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Ikena Oncology, Inc. will hold its 2024 Annual Meeting of Stockhold
Ikena Oncology Files 2023 Annual Report on Form 10-K — 10-K · Mar 12, 2024 Risk: medium
Ikena Oncology, Inc. (IMA) filed a Annual Report (10-K) with the SEC on March 12, 2024. Ikena Oncology, Inc. filed its 2023 Form 10-K on March 12, 2024. The com
SC 13G/A Filing — SC 13G/A · Mar 11, 2024
Ikena Oncology Reports Executive Changes and Compensation Arrangements — 8-K · Feb 21, 2024 Risk: medium
Ikena Oncology, Inc. filed an 8-K on February 21, 2024, reporting an event on February 20, 2024. The filing primarily concerns the departure of directors or cer
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
FMR LLC & Abigail Johnson Maintain 9.545% Stake in Ikena Oncology — SC 13G/A · Feb 9, 2024 Risk: low
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Ikena Oncology, Inc. (IKNA). As of February
Ikena Oncology Relocates HQ to 50 Northern Ave, Cuts Costs — 8-K · Jan 18, 2024
Ikena Oncology, Inc. filed an 8-K on January 17, 2024, to report that it is closing its office at 645 Summer Street, Suite 101, Boston, Massachusetts 02210, and

Risk Profile

Risk Assessment: Of IMA's 36 recent filings, 3 were flagged as high-risk, 19 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Imagenebio, INC.'s most recent 10-Q filing (Nov 12, 2025):

Revenue: $0
Net Income: -$24.779M
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $103.162M
Operating Margin: N/A
Total Assets: $160.878M
Total Debt: N/A

Key Executives

David P. Bonita
Kristin Yarema, Ph.D.
Patrick Loofbourrow, Esq.
Asa Henin, Esq.
Dr. David R. Walt
Dr. Jeffrey W. Almasleh
Abigail P. Johnson

Industry Context

ImageneBio operates in the highly competitive biotechnology sector, characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Success hinges on advancing novel drug candidates through clinical trials and securing regulatory approval. The industry faces constant pressure to innovate while managing high failure rates and substantial capital requirements.

Top Tags

Biotechnology (5) · 8-K (4) · acquisition (4) · 10-Q (4) · biotech (4) · executive-compensation (3) · governance (3) · Clinical Stage (3) · management-change (3) · corporate-governance (3)

Key Numbers

Document Size: 459534 — Size of the 424B3 filing document
Submission Text File Size: 466581 — Size of the complete submission text file
Acceptance Date: 2026-04-06 — Date the SEC accepted the filing.
Effectiveness Date: 2026-04-03 — Date the registration statement became effective.
SEC File Number: 001-40287 — Identifies the company's filing history with the SEC.
EIN: 81-1697316 — Employer Identification Number for tax purposes.
Fiscal Year End: 1231 — Indicates the end of the company's fiscal year for financial reporting.
Net Loss: $24.779M — Increased from $3.183M in Q3 2024, indicating higher burn rate.
Research and Development Expenses: $15.558M — Significantly up from $3.885M in Q3 2024, reflecting increased investment in IMG-007.
General and Administrative Expenses: $11.036M — Increased from $1.651M in Q3 2024, likely due to public company costs and operational expansion.
License Revenue: $0 — Down from $3.500M in Q3 2024, highlighting reliance on pipeline development.
Cash and Cash Equivalents: $103.162M — Substantially increased from $12.118M at Dec 31, 2024, providing a stronger cash runway.
PIPE Financing Proceeds: $71.130M — Key capital infusion contributing to the improved cash position.
Common Stock Shares Outstanding: 11,181,672 — As of Nov 3, 2025, reflecting dilution from reverse recapitalization and PIPE.
Total Assets: $160.878M — Increased from $15.922M at Dec 31, 2024, primarily due to cash and marketable securities.

Forward-Looking Statements

{"claim":"FMR LLC will maintain a significant ownership stake in Ikena Oncology, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"medium"}

Related Companies

ABBV · LLY · AMGN · IKNA · IMAG · BMY

Frequently Asked Questions

What are the latest SEC filings for Imagenebio, INC. (IMA)?

Imagenebio, INC. has 45 recent SEC filings from Jan 2024 to Apr 2026, including 23 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of IMA filings?

Across 45 filings, the sentiment breakdown is: 42 neutral, 3 mixed. The dominant sentiment is neutral.

Where can I find Imagenebio, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Imagenebio, INC. (IMA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Imagenebio, INC.?

Key financial highlights from Imagenebio, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for IMA?

The investment thesis for IMA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Imagenebio, INC.?

Key executives identified across Imagenebio, INC.'s filings include David P. Bonita, Kristin Yarema, Ph.D., Patrick Loofbourrow, Esq., Asa Henin, Esq., Dr. David R. Walt and 2 others.

What are the main risk factors for Imagenebio, INC. stock?

Of IMA's 36 assessed filings, 3 were flagged high-risk, 19 medium-risk, and 14 low-risk.

What are recent predictions and forward guidance from Imagenebio, INC.?

Recent forward-looking statements from Imagenebio, INC. include guidance on {"claim":"FMR LLC will maintain a significant ownership stake in Ikena Oncology, Inc. for the foreseeable future.","enti.